What is the recommended treatment for a dry cough accompanied by throat dryness?

Treatment for Dry Cough with Throat Dryness

For dry cough with throat dryness, use dextromethorphan as the primary cough suppressant, combined with a non-sedating antihistamine like bilastine if associated with upper respiratory symptoms, while avoiding sedating antihistamines unless nighttime cough disruption requires them. 1, 2

Initial Treatment Approach

First-Line Cough Suppressants

• Dextromethorphan is recommended as a central cough suppressant for short-term symptomatic relief of dry cough, particularly effective in chronic bronchitis but with limited efficacy in upper respiratory infections 1
• A recent 2024 trial demonstrated that bilastine 6.6 mg/dextromethorphan 20 mg/phenylephrine 10 mg combination is efficacious and non-sedating for acute dry cough, with significantly lower drowsiness scores compared to traditional sedating antihistamine combinations 2
• Codeine remains an option for chronic bronchitis-related cough but is NOT recommended for upper respiratory infection-related cough due to limited evidence 1

Antihistamine Selection

• Non-sedating antihistamines (bilastine) are preferred over first-generation sedating antihistamines to avoid daytime drowsiness 2
• Sedating antihistamines (chlorpheniramine, diphenhydramine) should be reserved specifically for nighttime cough that disrupts sleep, where sedation becomes therapeutically valuable 3
• The combination of codeine with chlorpheniramine is used in practice for nonspecific dry cough, though evidence is limited 3

Specific Clinical Scenarios

If Associated with Upper Respiratory Infection

• Ipratropium bromide (inhaled anticholinergic) is the ONLY recommended inhaled agent for cough suppression in URI or bronchitis 1
• Peripheral cough suppressants (levodropropizine, moguisteine) have limited efficacy in URI and are NOT recommended 1
• The bilastine/dextromethorphan/phenylephrine combination showed non-inferiority to traditional combinations with the advantage of being non-sedating 2

If Persistent Beyond 2 Weeks in Non-Smokers

• Consider inhaled fluticasone propionate 500 mcg twice daily for 2 weeks, which significantly reduces cough scores in otherwise healthy non-smoking adults 4
• This anti-inflammatory approach is effective only in non-smokers; smoking status completely negates the benefit of inhaled corticosteroids 4
• Complete resolution may require up to 8 weeks of treatment 1

Critical Pitfalls to Avoid

Smoking Status Matters

• Do not prescribe inhaled corticosteroids to active smokers for dry cough—they will not benefit 4
• Smoking status must be assessed before selecting anti-inflammatory therapy 4

Avoid These Common Errors

• Do not use mucolytic agents (agents that alter mucus characteristics) for cough suppression—they provide no benefit 1
• Do not use peripheral cough suppressants for URI-related cough—evidence shows they are ineffective in this setting 1
• Do not use codeine for URI-related cough—current guidelines specifically exclude this indication 1

When Symptomatic Treatment Fails

If dry cough persists despite appropriate suppressant therapy, systematic evaluation for underlying causes is mandatory:

• Upper airway cough syndrome (postnasal drip) should be evaluated first 1
• Asthma should be considered next, even without typical wheezing symptoms; bronchoprovocation challenge has nearly 100% negative predictive value 1
• Non-asthmatic eosinophilic bronchitis requires induced sputum analysis for eosinophils 1
• GERD should be evaluated if cough persists >2 months with normal chest X-ray, non-smoking status, no ACE inhibitor use, and failed treatment for upper airway and asthma causes 1

Practical Treatment Algorithm

1. Assess smoking status and duration of cough 4
2. For acute dry cough (<2 weeks): Start dextromethorphan-based combination with non-sedating antihistamine if daytime use needed 2
3. If nighttime cough disrupts sleep: Use sedating antihistamine/dextromethorphan combination 3
4. If URI/bronchitis symptoms present: Add ipratropium bromide inhaler 1
5. If persistent >2 weeks in non-smoker: Trial inhaled fluticasone 500 mcg twice daily 4
6. If no improvement after 2-4 weeks: Initiate systematic evaluation for underlying causes rather than continuing empiric suppressant therapy 1, 5